SecBot SecBot
SECBOTREPLAY Home › Report › BIOA

BIOA · BioAge Labs reported its full-year 2025 financial results alongside key…

BioAge Labs, Inc. · PRESS-RELEASE filed Mar 24, 2026 at 09:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 24, 2026 at 09:00 ET

BioAge Labs reported its full-year 2025 financial results alongside key clinical and corporate updates, including positive Phase 1 data for its NLRP3 inhibitor BGE-102, expansion into ophthalmology, and completion of a $132.3 million follow-on offering. The company now has $285.1 million in cash, funding operations through 2029. While collaboration revenue rose to $9.0 million, R&D and G&A expenses increased, resulting in a net loss of $80.6 million.

  • Positive interim Phase 1 data for BGE-102 showed 86% median reduction in hsCRP, 58% in IL-6, and 30% in fibrinogen in obese patients with elevated inflammation.
  • Phase 2a proof-of-concept trial in cardiovascular risk to initiate in 1H 2026; data expected in 2H 2026.
  • BGE-102 program expanded into diabetic macular edema (DME), with Phase 1b/2a trial planned for mid-2026.
  • Completed upsized follow-on offering raising $132.3 million in gross proceeds, strengthening cash position.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access